Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Biotherapy with interferon--1988.

R A Figlin1

  • 1Department of Medicine, UCLA School of Medicine 90024.

Seminars in Oncology
|December 1, 1988
PubMed
Summary
This summary is machine-generated.

Interferon therapy shows clinical activity across various cancers. However, antibody formation during treatment may impact treatment effectiveness, with varied clinical observations reported.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adjuvant therapy in renal cell carcinoma: does higher risk for recurrence improve the chance for success?

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

Integrating cytokines and angiogenic factors and tumour bulk with selected clinical criteria improves determination of prognosis in advanced renal cell carcinoma.

British journal of cancer·2017
Same author

Assessment of progression-free survival as a surrogate end-point for overall survival in patients with metastatic renal cell carcinoma.

European journal of cancer (Oxford, England : 1990)·2014
Same author

Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma.

British journal of cancer·2014
Same author

Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib vs interferon-α.

British journal of cancer·2012
Same author

Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-1 subgroup analysis.

British journal of cancer·2012
Same journal

A systematic scoping review of cancer-related anemia treatment: Comparative trial outcomes, current guidelines, and future perspectives.

Seminars in oncology·2026
Same journal

Steroid-induced tumor lysis syndrome in solid tumors: A case report and review of the literature.

Seminars in oncology·2026
Same journal

PSMA PET/CT staging in intermediate-risk prostate cancer: Toward risk-adapted implementation.

Seminars in oncology·2026
Same journal

Angiogenesis and the corresponding antiangiogenic therapy in gastroenteropancreatic neuroendocrine neoplasms.

Seminars in oncology·2026
Same journal

Post-translational regulation of steroidogenesis and its clinical relevance in hormone responsive cancers.

Seminars in oncology·2026
Same journal

Physics-informed machine learning for tumor microenvironment-responsive nanomedicine: Recent updates.

Seminars in oncology·2026
See all related articles

Area of Science:

  • Oncology
  • Immunology
  • Biotechnology

Background:

  • Interferon, a biologic response modifier, has been evaluated in numerous Phase I and II clinical trials for diverse cancers.
  • Recombinant DNA technology has enabled the production of interferons, which can elicit an immune response, including antibody formation.

Purpose of the Study:

  • To review the clinical activity of interferon in various malignancies.
  • To explore the factors influencing antibody formation in response to interferon therapy.
  • To discuss the implications of antibody formation on clinical outcomes.

Main Methods:

  • Review of Phase I and II clinical trial data for interferon in cancer treatment.
  • Analysis of factors associated with interferon-induced antibody production.

Related Experiment Videos

  • Synthesis of existing literature on the clinical impact of these antibodies.

    • Main Results:

    • Interferon demonstrates clinical activity in hematologic malignancies, lymphomas, and specific solid tumors like hairy-cell leukemia, Kaposi's sarcoma, and renal cell carcinoma.
    • Antibody formation against interferon is influenced by cancer type, interferon type, dosage, administration route, schedule, duration, and detection methods.
    • The clinical significance of interferon-induced antibodies is debated, with some studies suggesting abrogation of response and others finding no impact.

    Conclusions:

    • Interferon is an active agent in a wide range of cancers, but its efficacy can be complicated by the development of anti-interferon antibodies.
    • Further research is needed to clarify the precise role of these antibodies in modulating interferon's therapeutic effects across different malignancies.